Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures can be daunting—especially when Milestone Pharmaceuticals’ future hinges on each FDA interaction and every Phase 3 etripamil update. If combing through a 300-page 10-K for cash-runway clues or tracking Form 4 insider transactions feels overwhelming, you’re not alone. Milestone Pharmaceuticals insider trading Form 4 transactions, risk-factor shifts, and 8-K trial readouts arrive fast and in highly technical language.
Stock Titan turns that problem into clarity. Our AI-powered summaries translate Milestone Pharmaceuticals quarterly earnings report 10-Q filing details—burn rate, R&D spend, milestone payments—into plain English within minutes. Need real-time alerts? Milestone Pharmaceuticals Form 4 insider transactions real-time signals appear the moment executives buy or sell shares. Interactive dashboards connect each filing type to the questions investors actually ask: Milestone Pharmaceuticals annual report 10-K simplified for clinical timelines, Milestone Pharmaceuticals proxy statement executive compensation decoded, and Milestone Pharmaceuticals 8-K material events explained without legalese.
Because Milestone’s valuation swings with every clinical update, understanding Milestone Pharmaceuticals SEC documents with AI isn’t a luxury—it’s a necessity. Use our platform to:
- Compare quarter-over-quarter trial spending and cash equivalents
- Monitor executive stock transactions Form 4 ahead of pivotal data releases
- Follow shelf registration statements that may signal future capital raises
Milestone Pharmaceuticals Inc. reports that the U.S. Food and Drug Administration has approved its New Drug Application for CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT).
The company also furnished a new corporate presentation dated December 15, 2025, which is available as an exhibit and through the Investors & Media section of its website. Milestone states that it intends to use this website section to provide material information in line with Regulation FD, alongside press releases, SEC filings, and public calls or webcasts.
Milestone Pharmaceuticals Inc.'s chief commercial officer reported an insider transaction involving the company's common shares.
On 12/09/2025, the officer disposed of 25,000 common shares in a transaction coded "G", which the filing explains is a bona fide gift made for no consideration to members of the reporting person's family who live outside the reporting person's household.
Following this gift, the reporting person directly beneficially owns 150,052 common shares of Milestone Pharmaceuticals.
Milestone Pharmaceuticals (MIST) filed its Q3 2025 10‑Q. The company reported a net loss of
Liquidity strengthened after a July equity and warrant financing, bringing net proceeds of
Following a March 2025 Complete Response Letter for CARDAMYST (etripamil) in PSVT, the FDA accepted the company’s resubmission with a PDUFA target date of
Milestone Pharmaceuticals Inc. filed a Form S-8 to register an additional 4,000,000 common shares issuable under its 2019 Equity Incentive Plan, as amended, reflecting shareholder approval of the increase.
The filing incorporates by reference the Registrant's Annual Report for the fiscal year ended December 31, 2024, the Definitive Proxy Statement filed April 30, 2025, Quarterly Reports for the periods ended March 31, 2025 and June 30, 2025, various Current Reports and the Form 8-A description of common stock. Exhibits include amended organizational documents, the amended 2019 EIP, option and RSU award forms, legal opinions and consents.
Milestone Pharmaceuticals reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a regulatory and corporate update. The Form 8-K states the press release is attached as Exhibit 99.1 and is incorporated by reference; the filing text itself does not include the numerical results or detailed financial tables. The 8-K also lists the Interactive XBRL cover page file as Exhibit 104 and identifies the disclosure under the Results of Operations and Financial Condition item. Investors are directed to the attached press release for substantive figures and commentary.
Milestone Pharmaceuticals (MIST) delivered a mixed quarterly update focused on advancing its lead candidate, etripamil, while absorbing higher operating losses. For the six months ended June 30, 2025 the company reported a net loss of $33.7 million (net loss per share $0.51) and an accumulated deficit of $401.3 million. As of June 30, 2025, Milestone held $42.5 million in cash and $0.9 million in short-term investments (total ~$43.4 million) and reported total assets of $47.4 million and total liabilities of $65.2 million, including $55.2 million in senior secured convertible notes.
The FDA issued a Complete Response Letter in March 2025 citing CMC and inspection items but accepted Milestone’s June 13, 2025 response and set a PDUFA target date of December 13, 2025. A July 11, 2025 underwritten offering subsequently provided approximately $48.7 million of net proceeds and the RTW royalty agreement marketing deadline was extended to December 31, 2025. NODE-303 data showed a median time-to-conversion of 17 minutes with generally favorable tolerability. The company reported no revenue for the periods presented.
FAQ
What is the current stock price of Milestone Pharmaceuticals (MIST)?
What is the market cap of Milestone Pharmaceuticals (MIST)?
